Blue Owl Capital Holdings LP Grows Position in ImageneBio, Inc. $IMA

Blue Owl Capital Holdings LP raised its holdings in shares of ImageneBio, Inc. (NASDAQ:IMA) by 52.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 823,785 shares of the company’s stock after acquiring an additional 282,861 shares during the quarter. ImageneBio makes up about 0.4% of Blue Owl Capital Holdings LP’s investment portfolio, making the stock its 20th biggest position. Blue Owl Capital Holdings LP owned about 0.07% of ImageneBio worth $5,684,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Atlas Venture Life Science Advisors LLC bought a new stake in ImageneBio during the third quarter valued at about $3,079,000. BML Capital Management LLC bought a new stake in ImageneBio during the third quarter valued at about $1,487,000. Aldebaran Capital LLC bought a new stake in ImageneBio during the third quarter valued at about $159,000. Deep Track Capital LP bought a new stake in ImageneBio during the third quarter valued at about $7,160,000. Finally, Vanguard Group Inc. bought a new stake in ImageneBio during the third quarter valued at about $1,902,000. 75.00% of the stock is owned by institutional investors.

ImageneBio Stock Performance

Shares of IMA stock opened at $5.56 on Monday. ImageneBio, Inc. has a 12-month low of $3.94 and a 12-month high of $18.00. The stock’s 50-day moving average price is $5.56 and its 200-day moving average price is $6.40. The stock has a market capitalization of $59.24 million, a price-to-earnings ratio of -0.96 and a beta of 0.73.

ImageneBio (NASDAQ:IMA) last issued its earnings results on Thursday, May 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.25). As a group, research analysts predict that ImageneBio, Inc. will post -4.17 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have commented on IMA. Wall Street Zen cut ImageneBio from a “sell” rating to a “strong sell” rating in a report on Sunday, May 17th. Wedbush reissued an “underperform” rating on shares of ImageneBio in a report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, ImageneBio presently has a consensus rating of “Hold” and an average price target of $26.50.

About ImageneBio

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.